Questions Abound: UK MHRA Brexit Proposal For Medtech Leaves Much Unsaid, Much To Fear
Questions outnumber answers for medtech following the UK's recently issued "technical notices" on the implications if the UK does not reach a Brexit agreement with the EU before March 2019. Below we list the critical outstanding questions based on a Medtech Insight analysis and discussion with several top experts in the field. These questions have also been put directly to the UK's MHRA and the European Commission.
You may also be interested in...
As UK Prime Minister Theresa May tries to get her cabinet to accept the draft Brexit agreement between the UK and EU, Medtech Insight looks at the potential confusion for medtech should she fail.
The UK government has published a number of “technical notices” explaining what would change in the area of medical devices and pharmaceuticals in the event of a no-deal Brexit, and what stakeholders would need to do to prepare for such an eventuality.
While it was obvious to those in the sector that the implementation of the EU IVD Regulation was heading for a disaster, this article looks at the facts and figures that helped sway the European Commission to propose new transition periods to better manage its implementation.